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Enteroglucagon refers to the predominant peptide with glucagon-like immunoreactivity
(GLI) that is released by the intestine into the circulation in response to nutrients.
Development of a radioimmunoassay for glucagon revealed issues that were not
apparent in applications of the insulin radioimmunoassay. The fact that some antisera
raised against glucagon recognized glucagon-related peptides in extracts of both
pancreas and gut whereas others recognized only components in the pancreas
remained a mystery until it was realized that the “gut GLI cross-reactive” antisera were
directed against an epitope in the N-terminal to central region of glucagon whereas the
“pancreatic glucagon specific” antisera were directed against an epitope in the C-terminal
region. Unlike the cross-reactive antisera, the glucagon specific antisera did not recognize
components in which glucagon was extended from its C-terminus by additional amino
acids. Initial attempts to purify enteroglucagon from porcine ileum led to the erroneous
conclusion that enteroglucagon comprised 100 amino acids with an apparent molecular
mass of 12,000 Da and was consequently given the name glicentin. Subsequent work
established that the peptide constituted residues (1-69) of proglucagon (Mr 8128). In the
40 years since the structural characterization of glicentin, attempts to establish an
unambiguous physiological function for enteroglucagon have not been successful.
Unlike the oxyntomodulin domain at the C-terminus of enteroglucagon, the primary
structure of the N-terminal domain (glicentin-related pancreatic peptide) has been
poorly conserved among mammals. Consequently, most investigations of the
bioactivity of porcine glicentin may have been carried out in inappropriate animal
models. Enteroglucagon may simply represent an inactive peptide that ensures that the
intestine does not release equimolar amounts of a hyperglycemic agent (glucagon) and a
hypoglycemic agent (GLP-1) after ingestion of nutrients.
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Elucidation of the nucleotide sequence of a cDNA encoding human proglucagon (1) established
unambiguously that the molecule contained, in addition to glucagon, two additional regions whose
primary structures suggested that they represented biologically active peptides. In addition to domains
containing glucagon-like peptide-1 [GLP-1; proglucagon-(78-107) amide] and glucagon-like peptide-2n.org June 2021 | Volume 12 | Article 6830891
Conlon Enteroglucagon[GLP-2; proglucagon-(126-158)], a domain at the N-terminus of the
precursor contains enteroglucagon [proglucagon-(1-69) also known
as glicentin and gut glucagon-like immunoreactivity (GLI)]. Within
enteroglucagon, the sequences of glicentin-related pancreatic
peptide [GRPP; proglucagon-(1-30)], glucagon [proglucagon-(33-
61)] and oxyntomodulin [proglucagon-(33-69)] are embedded
(Figure 1). The story of the discovery of GLP-1 and GLP-2 and
the role of the truncated form of GLP-1 [proglucagon (78-107)
amide] as a physiologically important incretin and GLP-2 as a
trophic factor of intestinal mucosa has been told in several recent
comprehensive reviews (2–5) and so does not need re-telling in this
article. For the sake of clarity, an indication of the structural
relationships between these proglucagon-derived peptides is
provided in Table 1.
As a former post-doctoral fellow in the laboratories of Prof. Keith
D. Buchanan, Queen’s University of Belfast, N. Ireland (1974-7) and
Prof. Roger H. Unger, Southwestern Medical School, Dallas, U.S.A.
(1977-9), I will present in this article a somewhat personal
interpretation of the early literature relating to enteroglucagon prior
to the discovery of GLP-1 and GLP-2 in 1982. This is an attempt to
explain how a measure of order was brought to a thoroughly chaotic
situation regarding the measurement of GLI concentrations in
plasma and tissue extracts as well as how ambiguities regarding
structural characterization of the immunoreactive components were
resolved. Nevertheless, enteroglucagon and its N-terminal domain,




The discovery by Kimball andMurlin in 1923 of an hyperglycemic
factor in the pancreas, which they termed glucagon, isFrontiers in Endocrinology | www.frontiersin.org 2contemporaneous with the discovery of the hypoglycemic factor,
insulin (6) but it was not until 1957 that the primary structure of
the hormone was determined by Bromer and co-workers in the
Lilly Research Laboratories (7). Subsequent work by the group of
Sundby at Novo Nordisk demonstrated that, with the exception of
the hystricomorphs (8), the structure of the peptide has been very
strongly conserved among mammals including the human (9).
The presence of components with glucagon-like hyperglycemic
properties in extracts of intestinal mucosa was first reported by
Sutherland and De Duve in 1948 (10) but it was the development
of the first radioimmunoassay (RIA) for glucagon by the group of
Unger in 1961 (11), soon after the first reported RIA for insulin
(12), that permitted an investigation of the structure, distribution
and properties of enteroglucagon. However, it became apparent
that radioimmunoassays for glucagon were associated with
several issues that were not observed in applications of the
insulin radioimmunoassay.
The demonstration that gastrointestinal tissues contained
material that was recognized by antisera raised against glucagon
was made by Unger and co-workers in 1966 but they initially
concluded that “The results clearly indicate that glucagon or a factor
with the same immunochemical characteristics is present in acid-
alcohol extracts of gastrointestinal tissues of rat, dog andman.” (13).
The observation that glucagon-like material in the alimentary tract
was not identical to pancreatic glucagon was made by Samols andFIGURE 1 | A schematic representation of the structures of enteroglucagon (proglucagon-(1-69), glicentin-related polypeptide [GRPP; proglucagon (1-30)],
glucagon [proglucagon (33-61)] and oxyntomodulin [proglucagon (33-69)]. KR represents the dibasic residue processing sites. The blue bar indicates the epitope in
the N-terminal to central region of glucagon that is recognized by both “pancreatic glucagon-specific” and “gut GLI cross-reactive” antisera. The orange symbol





GLP-1 Proglucagon (72-107) amide
Truncated GLP-1 Proglucagon (78-107) amide
GLP-2 Proglucagon (126-158)June 2021 | Volume 12 | Article 683089
Conlon Enteroglucagonco-workers on the basis of non-parallelism of inhibition slopes
under RIA conditions (14). This conclusion was confirmed by the
demonstration that intraduodenal administration of glucose to dogs
resulted in a marked increase in GLI concentration in the
mesenteric vein but a decrease in the pancreatic venous effluent
and that the material released from the gut was chromatographically
different from that released from the pancreas (15).
It soon became apparent that antisera raised against glucagon
could be divided into two classes in terms of their ability to
recognize the glucagon-like components present in the
gastrointestinal tract. Antisera such as the widely distributed
Unger antiserum 30K (16) were described as “pancreatic
glucagon specific” because they measured only very low
concentration of GLI in extracts of intestinal tissues whereas
antisera, such as Heding antiserum K4023 (17) were described as
“gut GLI cross-reactive” because they detected high concentration of
GLI in both pancreatic and intestinal extracts. The molecular basis
for this difference in properties was elucidated by structure-
immunoreactivity studies using a range of glucagon fragments
(18, 19). As shown in Figure 1, the glucagon molecule is
associated with two antigenic sites. The “GLI cross-reactive”
antisera are directed against an epitope in the N-terminal to
central region of the peptide (residues 6-15) whereas the
“glucagon specific” antisera are directed against an epitope in the
C-terminal region of the peptide (residues 24-29) that requires
the presence of a free C-terminal carboxyl group for binding to
antibody. It was concluded, therefore, that enteroglucagon, like
oxyntomodulin, must comprise glucagon extended from its C-
terminus by additional amino acid residues. Conversely,
circulating components larger than glucagon that were detected
with C-terminally directed antisera must represent proglucagon-
derived peptides that lack this C-terminal extension (20).
Prior to the cloning era, our understanding of the nature of
proglucagon was complicated by reports that human (21) and
dog (22) plasma contained varying concentrations of a high
molecular mass component described as “big plasma glucagon”.
This component was eluted from gel permeation columns in the
globulin fraction of plasma (Mr >100,000 Da) and was detected
by both C-terminally and N-terminally directed antisera. Related
contemporary studies also described high molecular mass forms
of a number of other peptide hormones (ACTH, calcitonin,
gastrin, growth hormone, and LHRH) in human plasma by using
the techniques of gel permeation chromatography and
radioimmunoassay [reviewed in (23)]. Although the technique
of RIA has undoubtedly revolutionized the field of endocrinology,
inappropriate interpretation of RIA data has led to the appearance
of many articles in the literature for which the kindest description is
that they are irreproducible. It is frequently forgotten that RIA does
not measure directly the concentration of a component in a
biological fluid or tissue extract but the concentration of
substances that inhibit the binding of the radiolabeled tracer to
antibody. In this light, it became apparent that these “big plasma
hormones” represented factors, particularly a- and b-globulins, that
non-specifically inhibited binding of radiolabeled tracer to antibody
(23, 24). Consequently, it was concluded that removal of these
interfering components from plasma prior to assay, for example, by
selective ethanol precipitation was strongly advised, if notFrontiers in Endocrinology | www.frontiersin.org 3mandatory, for accurate determination of circulating glucagon
concentrations (25). By the same token, [125I]-labelled glucagon
tracers are rapidly degraded by peptidases in human plasma. The
inability of the damaged tracer to bind to antibody may also be
erroneously interpreted as the presence of antigen. Similarly, the
high molecular mass GLI component reported to be present in
extracts of salivary glands was shown to represent an artefact arising
from tracer-degrading activity (26). The problem was recognized
early and to some extent addressed by the inclusion of the peptidase
inhibitor Trasylol (Aprotinin) in the assay buffer (27) but
denaturation and precipitation of the degrading enzymes by
addition of ethanol is more effective in eliminating this
interference (25).STRUCTURAL CHARACTERIZATION
OF ENTEROGLUCAGON
The first suggestion that glucagon, like insulin, may be derived
from a biosynthetic precursor larger than itself was provided by
Tager and Steiner in 1973 who isolated and characterized
chemically a peptide impurity in a sample of bovine/porcine
glucagon. This component comprised glucagon extended from
its C-terminus by the octapeptide Lys-Arg-Asn-Asn-Lys-Asp-
Ile-Ala (28). The authors correctly speculated that the peptide,
subsequently shown to be identical to oxyntomodulin isolated
from porcine jejuno-ileum (29), represented a fragment
of proglucagon.
Prior to the availability of (relatively) affordable and reliable
equipment for HPLC in the 1980s, gel permeation chromatography
using columns of Sephadex G-50 or Biogel P-10 matrices was the
preferred method to purify partially and estimate the molecular
mass of peptides. However, the correlation between molecular mass
and elution volume is far from exact as interaction of the peptide
with the matrix is also dependent to some extent on molecular
charge and secondary structure. The major component of GLI in
extracts of porcine ileum (30, 31) and colon (32) and in canine brain
(33) was eluted from gel permeation chromatography columns with
the same elution volume as human cytochrome c (Mr 12,225 Da)
leading to the incorrect assumption that the molecular mass of
enteroglucagon was approximately 12,000 Da. A second component
in the extracts (subsequently identified as oxyntomodulin) was
eluted in a volume slightly less than that of glucagon indicating a
molecular mass of approximately 4,500 Da. The error in estimating
the molecular mass of enteroglucagon was compounded by the
report based upon amino acid composition analysis that porcine
enteroglucagon contained 100 amino acid residues, hence the term
glicentin (GLI-cent-in) was adopted (34). The article did, however,
lead to the recognition that enteroglucagon contained the full
sequence of glucagon and both peptides were derived from the
same biosynthetic precursor (35, 36).
Unambiguous determination of the primary structures of
porcine enteroglucagon (glicentin) (37) and GRPP (38) was
finally achieved by Thim and Moody. As shown in Figure 1,
glicentin comprises 69, not 100, amino acids (Mr 8128 Da) with
GRPP constituting the 30 amino-acid-residue N-terminalJune 2021 | Volume 12 | Article 683089
Conlon Enteroglucagondomain and oxyntomodulin the 37 amino-acid-residue
C-terminal domain. For those readers, such as myself, who
adopt a pedantic attitude to nomenclature, retention of the
term glicentin, especially when referring to enteroglucagon
from species other than the pig, is a source of minor irritation.THE SEARCH FOR A BIOLOGICAL ROLE
FOR ENTEROGLUCAGON
In contrast to the proglucagon-derived peptides oxyntomodulin,
GLP-1 and GLP-2, attempts to establish a well-defined
physiological function for enteroglucagon have been beset with
problems that still have not been resolved. Initial attempts to
determine such a function were hampered by the lack of
availability of pure peptide for use in bioassays.
Not long after the discovery of gut GLI, it was shown that an
extract of dog jejunum, partially purified by gel permeation
chromatography, lacked hyperglycemic activity when injected
endoportally into dogs, was devoid of glycogenolytic activity in
the isolated perfused rat liver and did not increase hepatic cAMP
concentrations (15). The observed glucagon-like ability of the
crude extract to stimulate insulin release from the perfused
pancreas was presumably a consequence of the presence of
GLP-1 and glucose-dependent insulinotropic polypeptide
(GIP). Material from porcine ileum (30) and colon (32) that was
purified to a higher degree by immunoaffinity chromatography
lacked lipolytic activity when incubated with chicken adipocytes,
was devoid of insulin-releasing activity in the isolated perfused rat
pancreas and did not activate adenylate cyclase in rat hepatocytes or
inhibit the binding of [125I]glucagon to liver plasma membranes. In
addition, the material did not display a cholecystokinin-like ability
to stimulate exocrine pancreatic section in the cat or inhibit the
stimulatory action of secretin (39).
Of some historical interest was the report that a patient with a
renal tumor releasing large amounts of enteroglucagon into the
circulation displayed, in addition to colonic and jejunal stasis and
malabsorption, marked small intestinal villous hypertrophy andFrontiers in Endocrinology | www.frontiersin.org 4these abnormalities disappeared following resection of the tumor
(40, 41). These observations led to speculation that enteroglucagon
may be functioning as a growth factor for the intestinal mucosa but
it now seems likely that GLP-2 co-released by the tumor was at least
partially responsible for the observed trophic effects.
Interest in the physiological function of enteroglucagon was
stimulated by the availability of highly purified porcine glicentin
provided by Novo Nordisk. However, unambiguous interpretation
of data obtained with this material is not always possible. Except in a
few cases, experimental studies have been carried out, not in pigs,
but in rodents, rabbits and dogs but, in contrast to glucagon and
oxyntomodulin, the primary structure of the N-terminal domain of
enteroglucagon (GRPP) has been poorly conserved among
mammals (Figure 2). Consequently, effects observed with
glicentin in such bioassays could be regarded as pharmacological
rather than physiological and conversely lack of effects may be a
consequence of differences in amino acid sequence. Additionally,
proteolytic conversion of glicentin to glucagon, glucagon fragments
and possibly oxyntomodulin by incubation with rat hepatocytes
(42) and enterocytes (43) has been demonstrated so that any
glucagon-like biological effects observed may be a consequence of
the in situ generation of these peptides. For example, glicentin had
1% of the potency of glucagon on glucose production when
incubated with hepatocytes but the peptide was concomitantly
degraded to smaller components some of which were
chromatographically very similar to glucagon and its fragments
suggesting that glicentin may exert its glucagon-like effects on
hepatocytes only after degradation to smaller glucagon-related
peptides (42). Similarly, oxyntomodulin and its (19–37) and
(30–37) fragments inhibit histamine-stimulated gastric acid
secretion in the rat (44) so that the observation that glicentin
infusions inhibit pentagastrin-stimulated gastric acid secretion in
the rat is subject to the interpretation that the effect may arise, at
least in part, from its conversion into these products (45).
More recent studies using synthetic GRPP and glicentin or
with naturally occurring peptides purified to near homogeneity
have been comprehensively reviewed by Raffort et al. (46).
However, the problem of interpretation of data generated by
peptides in heterologous animal models remains. For example,FIGURE 2 | A comparison of the primary structures of pig glicentin with enteroglucagon from human, rat, mouse, dog and rabbit, deduced from the nucleotide
sequences of cDNAs. Differences in amino acid sequence from the porcine peptide are shown in red. The glucagon sequence is underlined.June 2021 | Volume 12 | Article 683089
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an increase in plasma insulin and a decrease in plasma glucagon
(47) but rat GRPP elicited potent inhibition of glucose-stimulated
insulin secretion from the rat pancreas (48). Inconsistent results
have also been reported regarding trophic effects of glicentin on
intestinal mucosa and gastrointestinal motility that again may be
explained to some extent by species differences (46). The possibility
that enteroglucagon may have a function as a barrier-sustaining
agent was suggested by the report that recombinant human
enteroglucagon inhibited internalization of the bacteria Salmonella
enteritidis, Escherichia coli, and Enterococcus faecalis by INT-407
human-derived embryonic intestinal cells (49). This observation
may have clinical significance in terms of maintenance of the
integrity of tight junctions within in the intestine thereby
inhibiting extraintestinal invasion by pathogenic bacteria.CONCLUSION
It must be concluded that, at this time, the physiological role of
enteroglucagon remains unclear. A specific receptor for
enteroglucagon has not been identified and the fact that evolution
has not co-opted the large amounts that are released into the
circulation peptide for an hormonal function seems surprising.Frontiers in Endocrinology | www.frontiersin.org 5The pathways of differential processing of proglucagon by
prohormone convertases into predominantly GRPP, glucagon,
and a large inactive C-terminal fragment in the pancreas and to
enteroglucagon/oxyntomodulin, GLP-1 and GLP-2 in the gut are
well established (5). It makes little metabolic sense that the
mammalian intestine should release equimolar amounts of the
hyperglycemic factor, glucagon and the hypoglycemic factor GLP-
1 in response to ingested nutrients and so it may be that inactive
enteroglucagon simply represent nature’s strategy for obviating the
hyperglycemic action of proglucagon-derived peptides in the gut.AUTHOR CONTRIBUTIONS
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